CURRICULUM VITAE

SCOTT G. FOXMAN, M.D.
Retinal and Ophthalmic Consultants, P.C.

OFFICE LOCATIONS:

1500 Tilton Road, Northfield, NJ 08225

2466 East Chestnut Avenue, Vineland, NJ 08361

211 South Main Street, Cape May Court House, NJ 08210

PROFESSIONAL EXPERIENCE:

1986 - Present	Founder, President Retinal and Ophthalmic Consultants, P.C.

EDUCATION:

1973 - 1979	B.A. Boston University Medical Honors Program Boston University
1975 - 1979	M.D. Boston University Medical Honors Program Boston University

POSTDOCTORAL RESEARCH:

1979	National Eye Institute

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1979 - 1980	Intern in Medicine Jackson Memorial Hospital
1980 - 1983	Resident in Ophthalmology University of Minnesota, Minneapolis
1983 - 1985	Fellowship, Vitreoretinal Diseases Jules Stein Eye Institute, UCLA Los Angeles, California

FACULTY APPOINTMENTS:

1983 - 1985	Visiting Lecturer Jules stein Eye Institute University of California
1986 - Present	Courtesy Scheie Eye Institute

University of Pennsylvania School of Medicine

1986 - 1996	Associate Attending Ophthalmologist Division of Ophthalmology AtlantiCare Regional Medical Center
1997 - Present	Chief, Division of Ophthalmology AtlantiCare Regional Medical Center
1986 - Present	Assistant Attending Ophthalmologist Division of Ophthalmology Shore Memorial Hospital

SPECIALTY CERTIFICATION:

1979- Diplomat of the National Board of Medical Examiners

1984 - Diplomat of the American Board of Ophthalmology

LICENSURE: Pennsylvania, New Jersey

AWARDS AND HONORS:

NJ Top Docs 2017 and 2018 - 2019
Marquis Who's Who 2017 - 2019

PROFESSIONAL SOCIETIES:

National Societies

American Society of Retinal Specialists
American Academy of Ophthalmology
American Medical Association
Association for Research in Vision and Ophthalmology
American Board of Ophthalmology

Local Societies

Medical Society of New Jersey
Medical Society of Atlantic County
Academy of Medicine of New Jersey
New Jersey Academy of Ophthalmology
Retina Society of New Jersey

CLINICAL STAFF APPOINTMENTS:

AtlantiCare Regional Medical Center
Shore Memorial Hospital
Scheie Eye Institute

ACADEMIC APPOINTMENTS:

University of Pennsylvania, Courtesy Staff

BOARD POSITIONS:

Past President, Atlantic County Medical Society
Past President, Lions Club Vision Care Center

CHARITABLE POSITIONS:

Chairman, Leukemia Lymphoma Regatta, 2015
Co-Chairman, Leukemia Lymphoma Regatta, 2017

EDITORIAL POSITION:

Past Business Editor, American Society of Retina Specialists

RESEARCH: Principal and/or Sub-Investigator in over 35 National Clinical Studies

Amgen 20170542 – Sub Investigator
Amgen Inc. and Parexel International LLC
February 2020 – Present

A Randomized, Double-masked, Phase 3 Study of ABP938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects with Neovascular Age-related Macular Degeneration.

PANDA KHB-1802 – Sub-Investigator
Syneos Health, LLC
October 2019 – Present

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.

SAGA ALK001-P3001 – Sub-Investigator
Alkeus Pharmaceuticals, Inc.
October 2019 – Present

A Phase 2/3 Multicenter, Randomized, Double – masked, Parallel – group, Placebo- controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age – related Macular Dengeneration.

Yosemite GR40349 – Principal Investigate
F. Hoffmann-La Roche Ltd
July 2018 – Present

Phase III, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Efficacy and Safety of R06867461 in Patients with Diabetic Macular Edema

Aerpio AKB-9778-CI-5001 – Sub-Investigator
Aerpio Therapeutics LLC
August 2017 – Present

Phase III Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or 15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.

Omaspect Extension Study of Spectri GX30191 – Principal Investigator
F. Hoffman-La Roche Ltd
March 2017 – Present

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.

TOGA-01 Phase II/III – Principal Investigator
University of Virginia Department of Ophthalmology
February 2017 – Present

A Randomized, Double Masked, Placebo-Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.

MAKO-OHR-1601 / Chiltern Study Code No. 35544 – Sub-Investigator
OHR Pharmaceutical, Inc.
June 2016 – July, 2017

Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.

Capella R2176-3-AMD-1417 – Sub-Investigator
Regeneron
September 2015 – September 2016

A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration.

Spectri GX29185 – Principal Investigator
F. Hoffman-La Roche Ltd
August 2014 – Present

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to

Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

SCORE2 – Sub-Investigator
National Eye Institute, National Institutes of Health, Department of Health and Human Services
March 2014-2015

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2): A Multicenter, Prospective, Randomized, Phase III Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal aflibercept Every 4 Weeks.

ORBIT TG-MV-018 – Sub-Investigator
ThromboGenics, Inc.
February 2014-2015

A Multicenter, Prospective, Observational Phase 4 Study That Will Assess Clinical Outcomes and Safety of Jetrea Administered in a Real-World Setting for the Treatment of Symptomatic Vitreomacular Adhesion (VMA) by Assessing Anatomical and Functional Outcomes in 1500 Patients Recruited Across Approximately 120 USA Retina Sites.

Eclipse OPH1002A – Principal Investigator
Ophthotech Corp
September 2013 – August 2016

A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreou s Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.

BAM 114341 – Sub-Investigator
Glaxo Smith Kline
March 2013-2015

A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

VGFTe-AMD-1124 – Sub-Investigator
Regeneron
January 2013-2014

An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.

PROTOCOL S – Sub-Investigator
DRCR.net
July 2012-Present

Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Protocol V - Sub-Investigator
DRCR.net
July 2012-Present

Treatment for Central Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

VIBRANT – Sub-Investigator
Regeneron
June 2012-2013
Protocol: VGFT e-RVO -1027

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection(IAI) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

SAKURA-Principal Investigator
Santen Incorporated
2011-2013
Protocol No. 32-007:

A Phase III, Multinational, Multi-Center, Randomized, Double-Masked Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

VISTA – Sub-Investigator
Regeneron
2011-2013
VGFT-OD-1009

A Double-Masked, Randomized, Active-Controlled Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. PAREXEL #201601

SHORE-Principal Investigator
Genentech
2011-2013

BB-IND 8633-Protocol FVF4967g:

A Multi-Center Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.

VIEW 1 EXTENSION - Sub-Investigator
Regeneron
2010-2012
Protocol: VGFT-OD-0910

Open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration

NAION - Principal Investigator
Covance
2009-Present
Protocol: 12912

Prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).

COPERNICUS - Sub-Investigator
Regeneron
2009-April 2012
Protocol: VGFT-OD-0819

Randomized, double-masked, controlled phase III study of the efficacy, safety and tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).

HARBOR - Principle Investigator
Genentech
2009-2012
Protocol: FVF4579G

Phase III, double-masked, multi-center, randomized, active treatment, controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.

RISE - Principal Investigator
Genentech
2008-2012
Protocol: FVF4170G

Three-year multi-center study with monthly visits for patients with diabetic macular edema comparing Lucentis with Standard of Care Laser treatments.

CRUISE-Principal Investigator
Genentech
2008-2010
Protocol: FVF41669

One-year multi-center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.

DAVINCI - Sub-investigator
Regeneron
2008-2010
Protocol: VGFT-OD-0706

A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME).

HORIZON - Principal Investigator
Genentech
2008-2010
Protocol: FVF3426G

An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech-sponsored ranizumab study.

VIEW1 - Sub-Investigator
Regeneron
2007-2010
Protocol: VGFT-OD-0605

Two-year multi-center study with monthly visits comparing VEGF-Trap against Lucentis for patients with newly-diagnosed age-related macular degeneration.

SIRIUS - Sub-Investigator
Allergan
2006-2008
Protocol: 211745-001-01

Two-year multi-center study comparing Sirna against Lucentis for age-related macular degeneration

NOTAL VISION HMP-V4 - Sub-Investigator
Notal Vision
2006-2007
Protocol: 20071801

Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD).

SAILOR-Principal Investigator
Genentech, Inc.
2003-2007
Protocol: FVF3689G

One-year multi-center study to evaluate the safety and tolerability of Lucentis in newly-diagnosed and previously-treated subjects with age-related macular degeneration.

Visudyne Photodynamic Therapy - Sub-Investigator
Ciba Vision
1999-2000

Clinical Investigator for Visudyne Photodynamic Therapy study.

Flibanserin - Sub-Investigator
University of Pennsylvania and Boehringer Ingelheim (BI Trial No. 1997-1998)

Eight-week, double-blind, placebo-controlled Phase II study of various doses of flibanserin and paroxetine in patients with Major Depressive Disorder. Our role was to perform ophthalmic examinations to evaluate for potential ocular complications and side effects.

Pioglitazone - Sub-Investigator
Takeda America, Inc.
1996

A double-blind placebo-controlled, randomized, dose-titration study to evaluate the safety and efficacy of pioglitazone, an oral hypoglycemic agent. Our role was to perform retinal examinations and evaluate retinal photographs for evidence of diabetic retinopathy.

Adefovir Dipivoxil (bis-POM PMEA) - Sub-Investigator
NJCRI
1996-1997

A placebo-controlled study of the safety and efficacy of adefovir dipivoxil (bis-POM PMEA) in prolonged survival of HIV-infected individuals with a CD4+ cell count of $\leq 100/mm_3$. Our role was for ophthalmic evaluation with emphasis on the presence or absence of CMV retinitis.

Silicone Oil - Principal Investigator
Richard James Corporation
1993-1996

Principal Investigator. Clinical investigation as to the utility and safety of silicone oil injection in the vitreous cavity for patients with complicated retinal detachment. Our role was to provide patient care including vitreoretinal surgery.

Perfluorocarbon Liquid - Principal Investigator
Retinal and Ophthalmic Consultants, P.C.
1992-1996

Clinical investigation as to the utility and safety of intra-operative use of perfluorocarbon liquid into the vitreous cavity during surgical reattachment of the retina.

Sulfur hexafluoride and Perfluoropropane - Sub-Investigator
Retinal and Ophthalmic Consultants, P.C.
1989-1994

Clinical investigation as to the utility and safety of long-acting gases in the repair of retinal detachments.

Diabetic Retinopathy
National Institutes of Health
Early Treatment of Diabetic Retinopathy Study (ETDRS)
1984-1985

Dr. Scott Foxman was investigator in landmark national collaborative randomized trial of laser treatment for diabetic retinopathy.

PUBLICATIONS:

Original Papers

Ballantine, E., Foxman, S., Gorden, P., Rogh, J.: Rarity of Diabetic Retinopathy in Patients with Acromegaly. Arch. Intern. Med. 1981; 141:1625-1627.

Foxman, S., Cameron, J.D.: The Clinical Implications of Bilateral Microphthalmos with Cyst: Report of a Fatal Case. Am. J. Ophthalmol. 1984; 97:632-638.

Foxman, S., Heckenlively, J., Bateman, J., Wirtschafter, J.: A Classification of Congenital and Early Onset Retinitis Pigmentosa. Arch. Ophthalmol. 1985; 103:1502-1506.

Foxman, S., Heckenlively, J., Sinclair, S.: Pigmented Paravenous Retinochoroidal Atrophy and Rubeola Retinopathy. Am. J. Ophthalmol. 1985; 99:605-606.

Fishman, M., Kerman, B., Foxman, S.: Intraocular Cysticercus: Migratory. Ossonig, K. (ed): Proceedings of the 10th SIDUO Congress, Netherlands, W. Junk, 1986.

Heckenlively, J., Foxman, S., Parelhoff, E.: Retinal Dystrophty and Macular Coloboma. Doc Ophthal. 1988:68:257-271.

Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.

Foxman, S.: Finding the right fit: Considerations on both sides of the employment process. Retina Times. 2006:24:25-27.

Foxman, S.: Office Administrator: The guide of your practice's success. Retina Times. 2006:24:47-51.

Ferencz L, Lang J, Yeshurn I, Pollack A, Siegel R, Lifshitz T, Karp J et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2010 March.

Brown DM, Campochiaro PA, Singh RP, Li , Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizimab for macular edema following central retinal vein occlusion: Six month primary end-point results of phase III study. Ophthalmology. 2010 June; 117(6):1125-1133.e1.